Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06894329 · ClinicalTrials.gov registry record
A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions
A clinical trial of Pancreatic Cystic Lesions, sponsored by Amplified Sciences.
- Recruiting
- Registry status
- 50
- Enrollment target
- 3
- Study locations
NCT06894329: Recruiting study of Pancreatic Cystic Lesions, sponsored by Amplified Sciences.
NCT06894329 is a study of Pancreatic Cystic Lesions that is actively recruiting participants, run by Amplified Sciences. The registered enrollment target is 50 participants. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06894329, a study of Pancreatic Cystic Lesions, is actively recruiting participants, sponsored by Amplified Sciences.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research is to learn if the PanCystPro assay can help doctors in making decisions about treatment and monitoring of pancreatic cysts. The PanCystPro test measures glucose, carcinoembryonic antigen (CEA), and gastricsin biomarkers on fluid obtained from a pancreatic cyst. The test reports if the cyst fluid should be considered "Non-mucinous" or "Mucinous". Mucinous pancreatic cysts are more likely to progress to cancer while non-mucinous cysts seldom progress to cancer.
Primary Outcome
The percentage of subjects for which the providers indicated positive impact on patient management decisions of the PanCystPro assay results in patients with radiographically confirmed pancreatic cysts.
Conditions Studied
Study Locations (3)
Indiana
- Indiana University - Indianapolis
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New Jersey
- Rutgers Health - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-02-17 |
| Est. Completion | 2027-06-30 |
What NCT06894329 shows while recruiting
NCT06894329 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 1 condition, with Pancreatic Cystic Lesions appearing as the primary indexed condition, and to 0 interventions.
NCT06894329 reports a single indexed study location in Indiana, Massachusetts, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06894329 about?
NCT06894329 is a clinical study titled "A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions". The purpose of this research is to learn if the PanCystPro assay can help doctors in making decisions about treatment and monitoring of pancreatic cysts. The PanCystPro test measures glucose, carcinoembryonic antigen (CEA), and gastricsin biomarkers on fluid obtained from a pancreatic cyst. The test...
What is the current status of trial NCT06894329?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2026-02-17. Estimated completion is 2027-06-30.
What conditions does trial NCT06894329 study?
This clinical trial studies the following conditions: Pancreatic Cystic Lesions.
Who is sponsoring clinical trial NCT06894329?
This trial is sponsored by Amplified Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06894329 being conducted?
This trial has 3 study locations across Indiana, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cystic Lesions
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI